FIGURE 2 from Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Ida H., Shimizu T., Nishino M., Nakamura Y., Yazaki S., Katsuya Y., Sato J., Koyama T., Iwasa S., Sudo K., Kondo S., Yonemori K., Shitara K., Shiono S., Matsuoka D., Yasuda K., Otake Y., Suzuki T., Takase T., Takashima S., Yamaguchi K., Semba T., Yamamoto N.
<p>Percentage changes from baseline in sums of target lesion diameters over time per RECIST v1.1 by investigator assessment. Tumor types of patients with at least a 30% reduction at any timepoint are listed. <sup>a</sup>Plus nivolumab 360 mg every 3 weeks; <sup>b</sup>plus nivolumab 240 mg every 2 weeks. Q#W, every # weeks; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1.</p>